Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH)—a rare, aggressive ...

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class ...

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" ...

mAbs have already changed the landscape of cancer therapy, offering treatments that ... pushes the boundaries by demonstrating how 3E10 antibodies can penetrate cells and access their internal ...

In a new study, researchers evaluated the treatment effects of BI655064, an anti-CD40 monoclonal antibody, as an add-on ...

was published in Oncotarget's Volume 15 on November 22, 2024, titled "Advancements in cell-penetrating monoclonal antibody treatment." This new publication by Sai Pallavi Pradeep and Raman Bahal ...

Birtamimab is a monoclonal antibody commercialized by Prothena Corp, with a leading Phase III program in Primary Systemic Amyloidosis.

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class ...

The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...

The WVU Rockefeller Neuroscience Institute is providing patients greater statewide and regional access to a groundbreaking ...